Stepping down inhaled steroids can cut side effectsMay 21, 2003A ‘stepdown’ approach to reduce doses of inhaled steroids in patients with chronic asthma can cut the risk of side effects without compromising asthma control, say researchers in this week’s BMJ. Reduced dosages have already been achieved for people with mild asthma, but this is the first trial to look at those with chronic asthma. The study involved 259 patients in Scotland with chronic stable asthma, who were being treated with high dose inhaled corticosteroids. After a one month run-in period, patients were allocated to receive either a 50% reduction in their dose (stepdown group) or no alteration to their dose (control group). After one year, the team found no significant difference in the rate of asthma exacerbations or asthma events between the two groups. Inhaled corticosteroids are widely accepted as the treatment of choice for patients with chronic asthma. However, they have been associated with a number of dose related side effects including bruising, cataracts, and glaucoma, say the authors. This finding shows that a stepdown approach to inhaled corticosteroids can reduce the risk of steroid related side effects in this group of patients without compromising asthma control, they conclude. British Medical Journal (BMJ) |
|||||||||||||||||||||
| Related Asthma Current Events and Asthma News Articles Exposures to metals and diesel emissions in air linked to respiratory symptoms in children Exposure shortly after birth to ambient metals from residential heating oil combustion and particles from diesel emissions are associated with respiratory symptoms in young inner city children. Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later New research presents strong evidence that the "synergistic" effect of early-life exposure to both outdoor traffic-related pollution and indoor endotoxin causes more harm to developing lungs than one or the other exposure alone. Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps A protein known to stimulate blood vessel growth has now been found to be responsible for the cell overgrowth in the development of polyps that characterize one of the most severe forms of sinusitis, a study by Johns Hopkins researchers suggests. Ancestry attracts, but love is blind People preferentially marry those with similar ancestry, but their decisions are not necessarily based on hair, eye or skin colour. Common plastics chemicals linked to ADHD symptoms Phthalates are important components of many consumer products, including toys, cleaning materials, plastics, and personal care items. Asthma a significant risk factor for complications in children with H1N1 A new study on pediatric H1N1 influenza admissions has found that asthma is a significant risk factor for severe disease in children with pandemic H1N1 compared with the seasonal flu. Mother's Depression a Risk Factor in Childhood Asthma Symptoms, Study Suggests Asthma symptoms can worsen in children with depressed mothers, according to research from Johns Hopkins Children's Center published online in the Journal of Pediatric Psychology. Sweet -- sugared polymer a new weapon against allergies and asthma Scientists at Johns Hopkins and their colleagues have developed sugar-coated polymer strands that selectively kill off cells involved in triggering aggressive allergy and asthma attacks. Pivotal study for PSD502 -- the first potential treatment for premature ejaculation At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora" - AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE). Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor This research validates the potential for Stapled Peptides to modulate key intracellular biological targets, such as transcription factors, that have not been addressable with current small molecule or biologic drug modalities. More Asthma Current Events and Asthma News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||